Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 0.86 |
| ▸ | RARA | P10276 | 2/20 | 0.64 |
| ▸ | RARG | P13631 | 1/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | MPL | P40238 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20556345 | 0.98 | RARB (0.89) | RARBRARARARGAKR1C2AKR1C1 | |
| SCHEMBL4611393 | 0.93 | RARB (1.00) | RARBRARARARGMEN1ALDH1A1 | |
| SCHEMBL4187659 | 0.93 | RARB (1.00) | RARBRARARARGMEN1ALDH1A1 | |
| SCHEMBL2353325 | 0.87 | RARB (0.79) | RARBRARARARGMEN1ALDH1A1 | |
| SCHEMBL551744 | 0.86 | RARB (0.68) | RARBRARARARGAKR1C2AKR1C1 | |
| SCHEMBL2353664 | 0.84 | RARB (0.75) | RARBRARARARGMEN1ALDH1A1 | |
| SCHEMBL20556331 | 0.83 | RARB (0.68) | RARBRARARARGALDH1A1MCL1 | |
| SCHEMBL2362590 | 0.82 | RARB (0.71) | RARBRARARARGMEN1ALDH1A1 | |
| SCHEMBL2355289 | 0.81 | RARB (0.96) | RARBRARAMEN1ALDH1A1MAPT | |
| SCHEMBL20503376 | 0.80 | RARB (0.78) | RARBRARARARGMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | RARB 2792/4885RARA 2259/4885RARG 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.